Phase I Clinical Trial of Concurrent Paclitaxel, Carboplatin, and External Beam Chest Irradiation with Glutamine in Patients with Locally Advanced Non-Small Cell Lung Cancer

Autor:	M. M. Safa, Kevin P. Redmond, Abdul Rahman Jazieh, John A. Howington, Ralph Buncher, Ahmer Younas
Rok vydání:	2007
Předmět:	Male Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Paclitaxel medicine.medical_treatment Phases of clinical research Carboplatin chemistry.chemical_compound Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Lung cancer Aged Neoplasm Staging Chemotherapy Dose-Response Relationship Drug Radiotherapy business.industry Patient Selection Dose-Response Relationship Radiation General Medicine Middle Aged medicine.disease Radiation therapy Clinical trial Regimen chemistry Female business Esophagitis
Zdroj:	Cancer Investigation. 25:294-298
ISSN:	1532-4192 0735-7907
DOI:	10.1080/07357900701208758
Popis:	Esophagitis is a dose-limiting toxicity of combined chemoradiation therapy in patients with locally advanced lung cancer. Our study aimed at minimizing this complication by using glutamine in an attempt to escalate the dose of chemotherapy. This was a Phase I trial of escalating the dose of weekly paclitaxel and carboplatin with concurrent radiation therapy. Fifteen patients were enrolled, with median age 62 years (58-78), 13 males and 12 Caucasians. Due to multiple severe toxicities including hematological toxicities and esophagitis, the combination was deemed not feasible. In conclusion, the addition of glutamine does not prevent serious toxities of this concurrent chemoradiotherapy regimen.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d87af0234f6710111aa76f75baafbf5c https://doi.org/10.1080/07357900701208758 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.